BC
Birchview Capital Portfolio holdings
AUM
$171M
1-Year Est. Return
85.36%
This Fund
S&P 500
1 Year Est. Return
+85.36%
AUM
$132M
AUM Growth
+$31.8M
(+32%)
Holding
79
Top Buys
| 1 | +$5.63M | |
| 2 | +$2.76M | |
| 3 | +$1.6M | |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
+$1.16M |
| 5 |
Structure Therapeutics
GPCR
|
+$837K |
Top Sells
| 1 | +$1.13M | |
| 2 | +$830K | |
| 3 | +$753K | |
| 4 |
Axogen
AXGN
|
+$608K |
| 5 |
Xencor
XNCR
|
+$550K |
Sector Composition
| 1 | Healthcare | 76.79% |
| 2 | Technology | 17.82% |
| 3 | Energy | 4.7% |
| 4 | Materials | 0.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
KLA
KLAC
$187B
| $23.6M | 17.82% |
21,883
+6,035
|
|
||
2
Bristol-Myers Squibb
BMY
$124B
| $14.3M | 10.79% |
316,842
-6,516
|
|
||
3
Corcept Therapeutics
CORT
$3.62B
| $5.58M | 4.22% |
67,200
|
|
||
4
Prothena Corp
PRTA
$509M
| $5.36M | 4.05% |
549,019
+98,000
|
|
||
5
Stoke Therapeutics
STOK
$1.98B
| $4.93M | 3.73% |
210,000
|
|
||
6
uniQure
QURE
$663M
| $4.6M | 3.47% |
78,728
-19,969
|
|
||
7
Ovintiv
OVV
$14.9B
| $4.34M | 3.28% |
107,500
|
|
||
8
Neurocrine Biosciences
NBIX
$13B
| $4.03M | 3.04% |
28,690
-2,250
|
|
||
9
Acadia Pharmaceuticals
ACAD
$3.79B
| $3.65M | 2.76% |
171,000
-16,800
|
|
||
10
Protagonist Therapeutics
PTGX
$5.83B
| $3.19M | 2.41% |
48,000
|
|
||
11
Compass Therapeutics
CMPX
$984M
| $3.06M | 2.31% |
+872,938
|
|
||
12
Phreesia
PHR
$728M
| $2.7M | 2.04% |
114,700
|
|
||
13
Castle Biosciences
CSTL
$815M
| $2.52M | 1.9% |
110,600
|
|
||
|
14
Structure Therapeutics
GPCR
$4.22B
| $2.18M | 1.65% |
78,000
+42,000
|
|
||
15
Biodesix
BDSX
$126M
| $2.17M | 1.63% |
286,804
-2
|
|
||
16
QuidelOrtho
QDEL
$1.46B
| $2.14M | 1.61% |
72,548
|
|
||
|
17
Axogen
AXGN
$1.51B
| $2.12M | 1.6% |
119,078
-41,922
|
|
||
18
Amicus Therapeutics
FOLD
$4.5B
| $1.99M | 1.51% |
253,000
+225,000
|
|
||
19
Harrow
HROW
$1.34B
| $1.93M | 1.46% |
40,000
-20,000
|
|
||
20
EQT Corp
EQT
$38.5B
| $1.88M | 1.42% |
34,619
|
|
||
21
Solid Biosciences
SLDB
$437M
| $1.83M | 1.38% |
296,955
+118,187
|
|
||
22
Olema Pharmaceuticals
OLMA
$1.81B
| $1.7M | 1.29% |
174,000
+40,000
|
|
||
23
Cytokinetics
CYTK
$7.6B
| $1.65M | 1.24% |
30,000
+20,000
|
|
||
24
Alkermes
ALKS
$4.72B
| $1.5M | 1.13% |
50,000
|
|
||
25
Foghorn Therapeutics
FHTX
$330M
| $1.38M | 1.04% |
281,730
-29,200
|
|